[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tags-groups":3,"chains-groupcat":4,"tech-results-list":5,"achievements-hero-experts":321},[],[],{"list":6,"total":317,"page":318,"pageSize":319,"totalPages":320},[7,25,36,48,58,68,79,90,101,111,122,132,143,154,165,174,184,193,202,210,220,228,238,248,258,266,277,287,297,307],{"resultType":8,"id":9,"title":10,"abstract":11,"orgName":12,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":17,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":20,"ipc":21,"inventors":22,"tags":23,"tagNames":24},"patent","gpi_00274","15－氧代绣线菊内酯，其药物组合物和其制备方法及其应用","提供由结构式(1)所示的15－氧代绣线菊内酯(15－oxospiramilactone)化合物，其作为药物活性成分的抗肿瘤药物组合物，该化合物及其组合物可以克服因Bax缺失而引起的肿瘤细胞的抗药性以及克服Bcl－2高表达引起的肿瘤细胞对化疗药物的抗性，诱导Bcl－2高表达的细胞发生凋亡；诱导Bax和Bak双缺失的小鼠胚胎上皮细胞发生凋亡；抑制HCT116 Bax－\u002F－移植裸鼠肿瘤生长，显示15－氧代绣线菊内酯可以作为化疗药物，在杀伤对多种化疗药物有抗性的肿瘤细胞时，对动物体没有明显损害。","中国科学院昆明植物研究所;中国科学院动物研究所","530000;云南省","2026-10-12T00:54:35.109Z",null,"发明专利","2008.08.13#公开;2008.10.08#实质审查的生效;2012.01.04#授权",false,true,"CN200810058170.X","C07D311\u002F94;A61K31\u002F352;A61P35\u002F00","郝小江;陈全;刘海洋;赵丽霞;邸迎彤;金海京;何红平;乐雯;高锁;王晓慧;杜蕾",[],[],{"resultType":8,"id":26,"title":27,"abstract":28,"orgName":29,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":30,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":31,"ipc":32,"inventors":33,"tags":34,"tagNames":35},"gpi_00379","2型糖尿病疫苗的构建和制备方法","本发明提供一种2型糖尿病疫苗的构建和制备方法，将添加起始密码子ATG的人RBP－4活性蛋白编码基因插入T7噬菌体DNA衣壳蛋白10B编码基因的3’端，使人RBP－4蛋白与T7 10B表达成融合蛋白，构建成为重组噬菌体RBP\u002FT7，并进一步制备成重组噬菌体疫苗，免疫机体，刺激产生针对RBP－4的特异性抗体，调节体内的RBP－4水平，从而达到控制血糖的目的。经试验，构建的重组噬菌体疫能够有效降低KKAy小鼠血糖、甘油三酯和胆固醇，并能有效地保护KKAy小鼠，避免了其血糖水平的升高，同时增强了KKAy小鼠对葡萄糖灌胃和胰岛素注射的耐受性。因此用它治疗2型糖尿病，可彻底改变传统药物治疗存在的诸多不足或问题。","中国医学科学院医学生物学研究所","2008.11.19#公开;2009.01.14#实质审查的生效;2011.12.14#授权","CN200810058641.7","C12N15\u002F12;C12N15\u002F62;C12N7\u002F01;A61K39\u002F00;A61P3\u002F10","胡云章;胡凝珠;兰芸;王海漩;段金梅",[],[],{"resultType":8,"id":37,"title":38,"abstract":39,"orgName":40,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":41,"legalStatus":42,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":43,"ipc":44,"inventors":45,"tags":46,"tagNames":47},"gpi_01263","5-甲基-1,3苯二酚或其衍生物用于制备治疗或预防抑郁症的药物或功能食品中的用途","5-甲基-1，3苯二酚及其衍生物或含有它们的药物组合物用于制备治疗或预防抑郁症的药物或功能食品中的用途。研究表明，本发明的5-甲基-1，3苯二酚及其衍生物与抗抑郁症药物氟西汀或丙咪嗪相比具有较强的抗抑郁症活性。","中国科学院昆明植物研究所;中国科学院昆明动物研究所;昆明晶镖生物科技有限公司","PCT发明","2010.06.16#公开;2011.01.26#实质审查的生效;2013.01.23#授权","CN200880023868.6","A61K31\u002F05;A61K31\u002F085;A61K31\u002F7032;A61P25\u002F24;A23L1\u002F30","陈纪军;徐林;周俊;吕俊;毛榕榕;田孟;周启心;张雪梅;沈勇;江志勇;左爱学",[],[],{"resultType":8,"id":49,"title":50,"abstract":51,"orgName":29,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":52,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":53,"ipc":54,"inventors":55,"tags":56,"tagNames":57},"gpi_01042","EV71型病毒抗原的检测方法","本发明提供一种EV71型病毒抗原检测方法，它将待检EV71型病毒抗原、抗原阳性对照和抗原阴性对照分别加入酶标板的孔中，再在酶标板的各孔依次加入稀释度为1∶500～3000的生物素标记EV71型抗体，稀释度为1∶2000～10000的辣根过氧化物酶标记的链霉亲和素，TMB显色液A和B，最后在酶标板的各孔中加入终止液后，置于酶标仪上，在450nm波长下，用空白孔调零后检测吸光度A值，即得检测结果。本检测可从一般细胞培养病变法的3－5天缩短为数小时，在较短时间内确诊患者感染的病原体，且在基层医院和防控中心就可完成检测，能及时对症治疗和对疫情进行预防控制，是一种特异性好、灵敏度高、方便快捷的EV71病毒抗原检测方法。","2010.02.24#公开;2010.04.28#实质审查的生效;2014.04.23#授权","CN200910094972.0","G01N33\u002F569;G01N33\u002F543;G01N33\u002F52;G01N1\u002F34;C07K14\u002F085;C07K1\u002F14","李琦涵;谢忠平;龙润乡;董承红;杨蓉;白惠珠;李华;崔萍芳;刘龙丁",[],[],{"resultType":8,"id":59,"title":60,"abstract":61,"orgName":29,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":62,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":63,"ipc":64,"inventors":65,"tags":66,"tagNames":67},"gpi_00532","一种EV－71病毒毒种、人用灭活疫苗及其制备方法","本发明公开了一种EV－71病毒毒种、人用灭活疫苗及其制备方法。其毒种的分类命名为肠道病毒71型，保藏编号为CGMCC№.2701，所制成的人用EV－71灭活疫苗的组成为：EV－71活纯化抗原100μg\u002Fml，氢氧化铝0.8～1mg\u002Fml，硫柳汞0.05～0.1mg\u002Fml。试验表明该疫苗制品具有良好的免疫原性和安全性。","2009.04.08#公开;2009.06.03#实质审查的生效;2010.12.22#授权","CN200810233583.7","C12N7\u002F00;C12N7\u002F06;A61K39\u002F125;A61P31\u002F14","李琦涵;董承红;刘龙丁;谢忠平;王丽春;马绍辉;崔萍芳;梁燕;刘云霞;唐松清",[],[],{"resultType":8,"id":69,"title":70,"abstract":71,"orgName":72,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":73,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":74,"ipc":75,"inventors":76,"tags":77,"tagNames":78},"gpi_01463","一种利用大肠杆菌表达烟草富含甘氨酸RNA结合蛋白的方法","本发明公开了一种利用大肠杆菌表达烟草富含甘氨酸RNA结合蛋白(GRP)的方法，包括表达菌株筛选、培养基优化、蛋白提取缓冲液配制，其特征在于：具体包括下列工序：A、提取烟草总RNA，逆转录成cDNA，PCR扩增出GRP蛋白基因；B、构建重组表达质粒pGEX4T-1-GRP；C、转化大肠杆菌表达菌株、小量诱导筛选高效表达菌株、大量诱导表达；D、蛋白提取和E、蛋白活性鉴定。本发明通过筛选大肠杆菌高效表达菌株，优化培养基，克隆基因构建出GRP基因重组表达质粒pGEX4T-1-GRP，再用阳性质粒对菌种为rosetta的大肠杆菌菌株进行转化，并采用优化的专用培养基LinA培养、缓冲液TKM，筛选出了高效表达菌株，从而提高了烟草中富含甘氨酸RNA结合蛋白的表达效率。本发明具有成本低、操作简单、生产周期短、适于大规模生产、蛋白表达率高、活性强，易于纯化、不易降解的优点。","云南省烟草农业科学研究院","2010.09.08#公开;2010.10.27#实质审查的生效;2012.07.18#授权","CN201010110901.8","C12N15\u002F70;C12N15\u002F29;C12N1\u002F21;C07K14\u002F415","李文正;陈禹保;刘勇;陈学军;卢秀萍;唐启慧",[],[],{"resultType":8,"id":80,"title":81,"abstract":82,"orgName":83,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":84,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":85,"ipc":86,"inventors":87,"tags":88,"tagNames":89},"gpi_01411","一种制备毛萼乙素的方法","本发明涉及的是一种应用高速逆流色谱法从唇形科香茶菜属植物疏花毛萼香茶菜的粗提物中制备高纯度的毛萼乙素(eriocalyxin B)的方法，其特点是应用两相互不混溶的溶剂系统在支撑管内高速行星运动的方式下进行天然产物的分离纯化，因而没有不可逆吸附，具有样品无损失、无污染、高效、快速和大制量分离的优点，获得的毛萼乙素纯度可达98％以上，适用于从由各种工艺条件制备的疏花毛萼香茶菜粗品中分离制备毛萼乙素单体，适用于用各种型号的逆流色谱仪分离制备毛萼乙素单体。本发明制备方法操作简单、分离步骤少、效率高、溶剂损耗低、产品纯度高，适合工业化生产。","中国科学院昆明植物研究所","2010.08.18#公开;2010.10.06#实质审查的生效;2011.10.05#授权;2024.06.28#开放许可的声明及撤回","CN200910095183.9","C07D493\u002F10;B01D15\u002F18;B01D15\u002F20","孙汉董;韩全斌;普建新",[],[],{"resultType":8,"id":91,"title":92,"abstract":93,"orgName":94,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":95,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":96,"ipc":97,"inventors":98,"tags":99,"tagNames":100},"gpi_01788","一种制备灯盏花乙素的方法","本发明涉及一种结构式如式I所示化合物灯盏花乙素的制备方法。该方法以3，4，5-三甲氧基苯酚为起始原料，通过酰化成酯及酚酯重排、苯甲酰化成酯及Baker-Venkaraman重排、环合反应、脱甲氧基及乙酰化、烃化反应、氢解脱苄反应、烃化成苷反应、隔氧碱水解后用酸中和8个步骤制得高纯度的灯盏花乙素，本发明所述制备灯盏花乙素的方法产率高达20％以上，原料来源丰富，工艺简单，成本低，具有广泛的工业应用前景。","昆明制药集团股份有限公司;昆明理工大学","2011.01.12#公开;2011.03.09#实质审查的生效;2014.04.09#授权;2015.08.12#专利权人的姓名或者名称、地址的变更","CN200910140214.8","C07H17\u002F07;C07H1\u002F00;A61P7\u002F02;A61P9\u002F10;A61P9\u002F00","杨健;杨兆祥;杨波;普俊学;张伟;陈铎之",[],[],{"resultType":8,"id":102,"title":103,"abstract":104,"orgName":29,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":105,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":106,"ipc":107,"inventors":108,"tags":109,"tagNames":110},"gpi_00735","一种去除流感病毒原液中内毒素的方法","本发明提供一种从流感病毒原液中去除内毒素的方法，包括萃取分离，其特征在于在流感病毒原液中加入终浓度为0.5－5％(体积百分浓度)的介质——聚乙二醇单辛基酚醚，用于萃取分离流感病毒原液中的蛋白质和内毒素。可在不改变流感病毒原液原有性质的条件下，有效去除流感病毒原液中的内毒素，使内毒素含量降低到＜0.25EU\u002FmL，并保留流感病毒原液中的有效成分，达到优化质量的效果，本发明操作简单，内毒素去除率高，蛋白质总量回收率高达85％以上，血凝效价不变，血凝素含量回收率达99％以上，所得流感病毒原液安全、可靠。","2009.08.12#公开;2009.10.07#实质审查的生效;2012.03.21#授权","CN200910094192.6","C07K14\u002F11;A61P31\u002F16","李映波;黄秋香;毕湖冰;张新文;高菁霞;蔡玮;刘泽;姚忠萍;姜述德",[],[],{"resultType":8,"id":112,"title":113,"abstract":114,"orgName":115,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":116,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":117,"ipc":118,"inventors":119,"tags":120,"tagNames":121},"gpi_00303","一种城市电网最大供电能力在线评估方法","本发明涉及一种城市电网最大供电能力在线评估方法，属电力系统调度高级应用技术领域。本发明利用数据库连接方式(ADO与ODBC)，读取EMS中相关的网络拓扑及节点信息，借助邻接矩阵对城市电网进行拓扑分析，建立一种计算城市电网最大供电能力的模型，该模型是一种基于直流潮流的线性规划模型，它以网络所能供应的最大负荷为目标函数，以网络的功率平衡、各支路的额定容量、节点的功率约束为约束条件。在程序中利用改进单纯型法对线性规划问题进行求解，并对求解结果进行误差分析。该模型对于轻负荷网络具有计算速度快，计算结果误差不大的特点，适合应用于需要反复进行优化调整的电网中。应用该程序进行大量的计算，计算结果证明该方法的有效性和适用性。","昆明理工大学","2008.08.27#公开;2008.10.22#实质审查的生效;2013.06.12#授权","CN200810058263.2","H02J3\u002F00;G06F17\u002F00;G06Q50\u002F00","束洪春;胡泽江;董俊;刘可真;孙士云;唐岚;刘志坚;孙向飞;杨毅;常勇;单节杉;刘永泰",[],[],{"resultType":8,"id":123,"title":124,"abstract":125,"orgName":115,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":126,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":127,"ipc":128,"inventors":129,"tags":130,"tagNames":131},"gpi_00515","一种基于S变换的输电线路故障行波波头精确定位方法","本发明涉及一种基于S变换的输电线路故障行波波头精确定位方法，属电力系统继电保护技术领域。本方法为：对故障行波信号做数据窗截断，对少量关键数据进行S变换，S变换模矩阵表达了行波信号的幅值－时间－频率信息，依据行波波头和噪声在高频段不同频带的表现差异，将噪声影响基本滤除、并初步确定波头所在位置，然后重点考察最高频率点的幅值－时间曲线，其幅值最大值点将对应行波波头变化最剧烈点，即行波波头到达时刻点，并依据原始信号在此点附近的特征为波头打上极性信息。原理分析和仿真数据、工程数据验证表明，该方法对故障行波波头到达时刻标定准确，优于已有方法。","2009.03.25#公开;2009.05.20#实质审查的生效;2011.03.16#授权","CN200810058555.6","G01R31\u002F08;G06F17\u002F14","束洪春;程春和;王永治;董俊;刘志坚;刘可真;孙士云;唐岚;邱革非",[],[],{"resultType":8,"id":133,"title":134,"abstract":135,"orgName":136,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":137,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":138,"ipc":139,"inventors":140,"tags":141,"tagNames":142},"gpi_01751","一种天冬免疫佐剂及含有该佐剂的流感疫苗","本发明涉及一种天冬免疫佐剂及含有该佐剂的流感疫苗，其中天冬免疫佐剂由下列质量比的组分组成：天冬提取物0.001～100％，载体0～99.999％。所述含有天冬免疫佐剂的流感疫苗的组成是：天冬免疫佐剂与流感疫苗血凝素的质量比为50～180000。本发明提供的天冬佐剂具有显著的免疫佐剂效果，用于各种人、兽疫苗中，能起到有效的疾病防治作用。天冬提取物作为流感疫苗的免疫佐剂，与传统氢氧化铝佐剂比较，其使用安全性高、副作用小，能更好地提高流感疫苗免疫原性，在制备流感疫苗过程中，其方法简便，经济环保，质量容易控制，大大降低了流感疫苗抗原用量，能够满足流行性流感暴发时的免疫需求。","中国医学科学院医学生物学研究所;中国科学院昆明植物研究所","2010.12.29#公开;2011.02.16#实质审查的生效;2013.05.29#授权","CN201010256953.6","A61K39\u002F39;A61K39\u002F145;A61P31\u002F16","李映波;程永现;陈芹芹;吕青;李慧",[],[],{"resultType":8,"id":144,"title":145,"abstract":146,"orgName":147,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":148,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":149,"ipc":150,"inventors":151,"tags":152,"tagNames":153},"gpi_00065","一种新型环状小肽BA及其应用","本发明涉及一种新型环状小肽BA及其应用，属于生物医学技术领域。本发明的环状小肽BA，分子量1259.56道尔顿，等电点4.44，具有一定的丝氨酸蛋白酶抑制剂活性，无酶活性。其全序列为：Cys Trp Thr Lys Ser Ile Pro ProLys Pro Cys(CWTKSIPPKPC)，第1位半胱氨酸和第11位的半胱氨酸形成分子内二硫键。该环状小肽BA作为药物设计模版及作为制备治疗肿瘤药物的应用。以环状小肽BA作为模版，在其氨基端和羰基端分别进行不同氨基酸的增加，得到具有抗菌活性或丝氨酸蛋白酶抑制剂活性的环状小肽BA1和环状小肽BA2，并作为制备治疗肿瘤、胃炎、胰腺炎药物的应用。本发明还具有序列简单、合成方便等优点。","中国科学院昆明动物研究所","2007.08.29#公开;2007.10.24#实质审查的生效;2009.08.05#授权","CN200710065665.0","C07K7\u002F06;C07K7\u002F08;A61K38\u002F08;A61K38\u002F10;A61K38\u002F16;A61P35\u002F00;A61P1\u002F04;A61P1\u002F18","赖仞;李建许;李东升",[],[],{"resultType":8,"id":155,"title":156,"abstract":157,"orgName":158,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":159,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":160,"ipc":161,"inventors":162,"tags":163,"tagNames":164},"gpi_01426","一种治疗乳腺病的药物","一种治疗乳腺病的药物，由下述重量份的药材制成：益母草1-3，粗叶木1-3，莪术1-3，丹参1-3，三台红花0.5-1，元胡1-2，香附子1-3，蒲公英1-3，芒硝1-2；本发明采用的几种药材组成的各方，全方合用，共同发挥活血化瘀，软坚散结，消肿止痛之疗效，以达到清火解毒，通气活血，化瘀止痛，消肿散结之目的，应用现代技术研制成不同的剂型应用于临床，收到显著的疗效。","西双版纳傣族自治州民族医药研究所","2010.08.25#公开;2010.10.13#实质审查的生效;2011.12.07#授权","CN201010171179.9","A61K36\u002F9066;A61P15\u002F14;A61K33\u002F04;A61K35\u002F02;A61K35\u002F36;A61K35\u002F56","林艳芳;段立纲;赵应红;岩罕单;廖瑞玲;玉腊波;谭志刚;潘玉秀;刀红英;曾君;王孝蓉;肖丽香;刀会仙;陈亚梅;刘志强;邓群;刘扬扬",[],[],{"resultType":8,"id":166,"title":167,"abstract":168,"orgName":158,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":169,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":170,"ipc":171,"inventors":162,"tags":172,"tagNames":173},"gpi_01428","一种治疗妇科疾病的药物","一种治疗妇科疾病的药物，由下述重量份的原料药材制成：百样解5份，勐腊大解药3.6份，益母草3.3份，白花臭牡丹根3.5份，姜黄2.7份，定心藤2.7份，元胡1份，旱莲草1份；本发明是基于中国传统医学中的傣医解毒理论的治疗原则，从傣医传统解毒药物和清热解毒，活血调经处方中筛选研究加减发展而来，结合现代制药技术在原汤药基础上、研制了散剂、胶囊剂、片剂和颗粒剂等现代剂型，使其既具傣医药传统特色，又有现代制剂特点。","2010.08.25#公开;2010.10.13#实质审查的生效;2012.07.18#授权","CN201010171324.3","A61K36\u002F9066;A61P15\u002F00",[],[],{"resultType":8,"id":175,"title":176,"abstract":177,"orgName":158,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":178,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":179,"ipc":180,"inventors":181,"tags":182,"tagNames":183},"gpi_01470","一种治疗泌尿系感染和结石病的药物","一种治疗泌尿系感染和结石病的药物，由下述重量份的药材制成：盾翅藤1-5，野芦谷根1-3，圆锥南蛇藤1-3，肾茶1-3，甘草1-2；本发明制备的药品用于治疗急、慢性肾炎，肾盂炎，尿路感染，肾、输尿管、膀胱结石等病症；应用现代技术研制成不同的剂型应用于临床，收到显著的疗效，经临床疗效观察和急毒试验，主要药效学研究证明，未发现毒副反应，疗效安全可靠，疗效显著，具有很好的开发应用前景和市场竞争力。","2010.09.15#公开;2010.11.03#实质审查的生效;2012.07.04#授权","CN201010171168.0","A61K36\u002F53;A61P13\u002F00;A61P31\u002F00;A61P13\u002F04;A61P13\u002F12;A61P13\u002F02;A61K35\u002F37","段立纲;林艳芳;赵应红;岩罕单;廖瑞玲;玉腊波;谭志刚;潘玉秀;刀红英;曾君;王孝蓉;肖丽香;刀会仙;陈亚梅;刘志强;邓群;刘扬扬",[],[],{"resultType":8,"id":185,"title":186,"abstract":187,"orgName":158,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":188,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":189,"ipc":190,"inventors":162,"tags":191,"tagNames":192},"gpi_01471","一种治疗疔疮的外搽酊剂","一种治疗疔疮的外搽酊剂，由下述重量份的原料药制成：余甘子树皮1-4，云南石梓树皮1-4，台乌1-4，十大功劳1-3，雄黄1-3；本发明提供的药物具有清热解毒，收敛止痒的功能；该药物经临床疗效观察和急毒试验，未发现毒副反应，疗效安全可靠，疗效显著，具有很好的开发应用前景和市场竞争力。","2010.09.15#公开;2010.11.03#实质审查的生效;2011.12.07#授权","CN201010171251.8","A61K36\u002F85;A61K9\u002F08;A61P17\u002F00;A61P31\u002F22;A61P17\u002F04;A61K33\u002F36",[],[],{"resultType":8,"id":194,"title":195,"abstract":196,"orgName":158,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":197,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":198,"ipc":199,"inventors":162,"tags":200,"tagNames":201},"gpi_01424","一种治疗糖尿病的药物","一种治疗糖尿病的药物，由下述重量份的药材制成：南沙参1-10，麦冬1-4，天冬1-3，石斛1-3，天花粉1-2.5，葛根1-3，百样解1-7，十大功劳1-2.5；用于治疗糖尿病多饮、多食、尿多、形瘦体弱。经临床用药，并对其进行初步的急毒研究及临床疗效的观察，对糖尿病具有显著疗效，未发现毒副反应，对糖尿病病人具有保护脏器、降低血糖、改善临床诸症等作用。","2010.08.25#公开;2010.10.13#实质审查的生效;2011.11.09#授权","CN201010171195.8","A61K36\u002F8984;A61P3\u002F10",[],[],{"resultType":8,"id":203,"title":204,"abstract":205,"orgName":158,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":188,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":206,"ipc":207,"inventors":162,"tags":208,"tagNames":209},"gpi_01474","一种治疗肝病的药物","一种治疗肝病的药物，由以下重量份的药物组成：柴胡1，百样解4，十大功劳1.25，枸杞2.25，五味子1.75，丹参1.25，山楂3.5，槟榔2.5，甘草0.5；有健脾舒肝，活血止痛，保肝利胆之功能。用于治疗肝胆功能失调，胆汁、毒物排泄失常而发生的肝胆疾病，如甲、乙肝病、脂肪肝、酒精肝、肝癌、胆囊炎、胆石症等。","CN201010171271.5","A61K36\u002F898;A61K36\u002F9066;A61P1\u002F16;A61P31\u002F14;A61P31\u002F20;A61P35\u002F00",[],[],{"resultType":8,"id":211,"title":212,"abstract":213,"orgName":115,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":214,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":215,"ipc":216,"inventors":217,"tags":218,"tagNames":219},"gpi_01894","一种特高压直流输电线路故障智能分类与测距方法","一种特高压直流输电线路故障智能分类与测距方法，属电力系统继电保护技术领域。本发明采用分层分布式神经网络模型，用一个神经网络先对故障数据进行分类，区分故障的类型，而后将分类的数据分别送入不同的神经网络进行故障测距。当直流线路发生故障后，采样频率为10kHz，选取故障后采样序列长度为100的离散线模电压信号，进行S变换，变换结果为一51×100的复时频矩阵，并对此复矩阵中的各个元素求模，得到线模电压在各频率上的暂态能量分布，选取能谱中前5项作为样本属性，选择传递函数和学习规则，设置合适的神经网络参数构造出BP网络模型，进行故障分类和故障定位。大量仿真结果表明，本发明效果良好。","2011.02.16#公开;2011.03.30#实质审查的生效;2012.07.04#授权","CN201010274142.9","G01R31\u002F08;G06N3\u002F08","束洪春;戴月涛;田鑫萃;张广斌;孙士云;白挺伟",[],[],{"resultType":8,"id":221,"title":222,"abstract":223,"orgName":158,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":197,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":224,"ipc":225,"inventors":181,"tags":226,"tagNames":227},"gpi_01427","一种用于治疗胃病的药物","一种用于治疗胃病的药物，由下述重量份的药物制成：姜黄1-4.5、莪术1-4.5、黄姜1-4.5、九翅豆蔻2-5、黄樟树心1-5、鸡矢藤3-7、山大黄1-3、山乌龟0.5-1.5；用于治疗胃病，如急、慢性胃炎、肠炎、胃窦炎、胃溃疡、消化不良、胆囊炎、结石等引起的胃脘疼痛，经临床疗效观察和急毒试验研究证明，未发现毒副反应，安全可靠且疗效显著。","CN201010171288.0","A61K36\u002F9066;A61P1\u002F04;A61K35\u002F56",[],[],{"resultType":8,"id":229,"title":230,"abstract":231,"orgName":147,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":232,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":233,"ipc":234,"inventors":235,"tags":236,"tagNames":237},"gpi_00138","一种电刺激噪声消除仪","本发明公开了一种电刺激噪声消除仪，包括两根用于采集生物电信号的微电极，所述微电极的信号输出端经噪声抑制电路后输出，所述噪声抑制电路包括差分放大电路和电阻电容补偿电路，所述微电极采集的电信号经电阻电容补偿电路，分别输入差分放大电路的两个输入端，经差分放大之后输出。利用本发明所述电刺激噪声(伪迹)消除仪，可以消除大于生物电信号本身约40倍以上的电刺激噪声，从而有利于实现将电刺激和单位放电记录这两项重要的神经电生理研究技术有机的结合起来，对神经电生理的研究具有积极的促进作用。","2008.03.12#公开;2008.05.07#实质审查的生效;2010.11.24#授权","CN200710031057.8","A61B5\u002F0476","胡新天;马原野",[],[],{"resultType":8,"id":239,"title":240,"abstract":241,"orgName":29,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":242,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":243,"ipc":244,"inventors":245,"tags":246,"tagNames":247},"gpi_00061","一种轮状病毒灭活疫苗的制备方法","本发明公开了一种轮状病毒灭活疫苗的制备方法。该方法使轮状病毒株G1，G2，G3，G4适应至人二倍体细胞系，并在人二倍体细胞系上高效繁殖，将制得的轮状病毒作为轮状病毒灭活疫苗的生产毒株。其中，所述的人二倍体细胞系为KMB17。本发明选用人二倍体细胞系作为灭活轮状病毒疫苗生产的细胞基质，与现有的其它细胞基质相比，更安全。因此，利用建立的技术平台，可以采用轮状病毒的其它血清型作为研究对象，开发成为轮状病毒灭活疫苗。","2007.08.22#公开;2007.10.17#实质审查的生效;2010.12.29#授权","CN200710065708.5","A61K39\u002F15;A61P31\u002F14;C12N7\u002F00;C12N5\u002F08","刘馨;孙茂盛",[],[],{"resultType":8,"id":249,"title":250,"abstract":251,"orgName":136,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":252,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":253,"ipc":254,"inventors":255,"tags":256,"tagNames":257},"gpi_01659","一种锁阳免疫佐剂及含有该佐剂的流感疫苗","本发明涉及一种锁阳免疫佐剂及含有该佐剂的流感疫苗，其中锁阳免疫佐剂由下列质量比的组分组成：锁阳提取物0.001～100％，载体0～99.999％。所述含有锁阳免疫佐剂的流感疫苗的组成是：锁阳免疫佐剂与流感疫苗血凝素的质量比为50～150000。本发明提供的锁阳佐剂具有显著的免疫佐剂效果，用于各种人、兽疫苗中，能起到有效的疾病防治作用。锁阳提取物作为流感疫苗的免疫佐剂，与传统氢氧化铝佐剂比较，其使用安全性高、副作用小，能更好地提高流感疫苗免疫原性，在制备流感疫苗过程中，其方法简便，经济环保，质量容易控制，大大降低了流感疫苗抗原用量，能够满足流行性流感暴发时的免疫需求。","2010.12.01#公开;2011.01.12#实质审查的生效;2013.12.04#授权","CN201010230599.X","A61K39\u002F39;A61K39\u002F145;A61K36\u002F185;A61P31\u002F16;A61P37\u002F04;A61K135\u002F00","李映波;程永现;毕湖冰;吕青;陈芹芹",[],[],{"resultType":8,"id":259,"title":260,"abstract":261,"orgName":136,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":262,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":263,"ipc":139,"inventors":140,"tags":264,"tagNames":265},"gpi_01750","一种鳖甲免疫佐剂及含有该佐剂的流感疫苗","本发明涉及一种鳖甲免疫佐剂及含有该佐剂的流感疫苗，其中鳖甲免疫佐剂由下列质量比的组分组成：鳖甲提取物0.001～100％，载体0～99.999％。所述含有鳖甲免疫佐剂的流感疫苗的组成是：鳖甲免疫佐剂与流感疫苗血凝素的质量比为50～180050。本发明提供的鳖甲佐剂具有显著的免疫佐剂效果，用于各种人、兽疫苗中，能起到有效的疾病防治作用。鳖甲提取物作为流感疫苗的免疫佐剂，与传统氢氧化铝佐剂比较，其使用安全性高、副作用小，能更好地提高流感疫苗免疫原性，在制备流感疫苗过程中，其方法简便，经济环保，质量容易控制，大大降低了流感疫苗抗原用量，能够满足流行性流感暴发时的免疫需求。","2010.12.29#公开;2011.02.16#实质审查的生效;2012.10.10#授权","CN201010256942.8",[],[],{"resultType":8,"id":267,"title":268,"abstract":269,"orgName":270,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":271,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":272,"ipc":273,"inventors":274,"tags":275,"tagNames":276},"gpi_01086","乌药烷型二聚倍半萜类化合物,其制备方法及其在制药中的应用","本发明涉及从金粟兰属(Chloranthus)植物中分离得到的乌药烷型二聚倍半萜类(结构式I和II)化合物，它们的制备方法，以及在治疗2型糖尿病、肥胖症及其它引起的并发症的药物中的应用。式I和II中R1－R17为氢，或氧，或羟基，或酰基(乙酰基、当归酰基、羟基当归酰基、惕各酰基、千里光酰基、羟基千里光酰基、羧基千里光酰基、1，4－丁二酰基)，或双键、或烷基(甲基)，或R16和R17之间可以形成大环内酯，X为氧或氮。通过生物实验证明本发明的化合物具有较强的胰岛素增敏活性。","中国科学院昆明植物研究所;昆明医学院","2010.03.17#公开;2010.04.28#实质审查的生效;2012.05.02#授权;2022.06.28#专利实施许可合同备案的生效、变更及注销","CN200910095051.6","C07D493\u002F10;C07D493\u002F20;C07D307\u002F94;A61K31\u002F365;A61P3\u002F10;A61P3\u002F04;A23L1\u002F29","刘海洋;李玲;陈昌祥;孙玲;藤菲;黄年旭;冉新辉;倪伟;郝小江;高锁",[],[],{"resultType":8,"id":278,"title":279,"abstract":280,"orgName":29,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":281,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":282,"ipc":283,"inventors":284,"tags":285,"tagNames":286},"gpi_00980","乙型流感病毒Vero细胞高产适应株及其制备和应用","本发明提供一种乙型流感病毒Vero细胞高产适应株及其制备和应用。所述乙型流感病毒Vero细胞高产适应株命名为：B\u002FYunnan\u002F2\u002F2005va(B)，该毒株保藏号为：CGMCCNo.2931。该毒株能在Vero细胞上连续传代培养，并且血凝效价可保持在1∶512以上。经检测，该毒株为乙型流感病毒，Yamagata谱系。该毒株含有乙型流感病毒的八个基因片段，且具有Vero细胞上持续高产的特性。一方面，将该毒株接种于Vero细胞，收集培养物上清，即得乙型流感病毒疫苗，实验证实，该疫苗具有良好的免疫原性和保护效力。另一方面，该毒株也可作为供体毒株，通过自然选择压力重配或反向遗传学重配，得到流行株在Vero细胞上的适应株，从而制备出流行株Vero细胞流感疫苗。","2010.01.06#公开;2010.03.03#实质审查的生效;2011.08.24#授权","CN200910094354.6","C12N7\u002F00;C12N7\u002F08;A61K39\u002F145;A61P31\u002F16;C12N15\u002F85;C12N7\u002F01;C12R1\u002F93","廖国阳;刘泽;孙明波;李卫东;高菁霞;马磊;周健;张新文;蔡玮;姜述德",[],[],{"resultType":8,"id":288,"title":289,"abstract":290,"orgName":83,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":291,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":292,"ipc":293,"inventors":294,"tags":295,"tagNames":296},"gpi_01355","二倍半萜化合物及其应用","提供式(I)二倍半萜类化合物，其制备方法，以及以该类化合物为活性成分的抑制血管生成和抗脯氨酰内肽酶，抗菌，拒食，香料方面的应用。","2010.07.28#公开;2010.09.22#实质审查的生效;2011.07.20#授权","CN201010109384.2","C07D307\u002F77;C07D307\u002F46;A61K31\u002F365;A61P31\u002F04;A61P35\u002F00;A61P25\u002F28;A61P3\u002F04;C11B9\u002F00","黎胜红;骆世洪",[],[],{"resultType":8,"id":298,"title":299,"abstract":300,"orgName":83,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":301,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":302,"ipc":303,"inventors":304,"tags":305,"tagNames":306},"gpi_01879","以土大黄提取物为有效成份的抗焦虑药物及其制备方法和应用","以土大黄提取物或有效部位为主要有效成份制备的药物，以中药材土大黄为主要有效成份制成片剂、颗粒剂、胶囊剂、口服液等口服给药剂型，可加入其它成份和辅料组成复方制剂，具有显著的抗焦虑效果，可用于焦虑症的保健和治疗。此外，还提供以土大黄提取物和食品添加剂组合成的保健食品，药物和食品的制备方法。","2011.02.16#公开;2011.03.30#实质审查的生效;2011.11.16#授权","CN201010506212.9","A61K36\u002F70;A23L1\u002F30;A61P25\u002F22","程永现;梅任强;陈小亮;赵君",[],[],{"resultType":8,"id":308,"title":309,"abstract":310,"orgName":29,"province":13,"date":14,"trl":15,"transferMode":15,"keywords":15,"industry":15,"patentType":16,"legalStatus":311,"isOpenLicense":18,"isRevitalized":19,"techMaturity":15,"starRating":15,"licenseFeeText":15,"patentNo":312,"ipc":313,"inventors":314,"tags":315,"tagNames":316},"gpi_00420","冻干甲型肝炎减毒活疫苗及其制备方法","本发明涉及一种冻干甲型肝炎减毒活疫苗及其制备方法，所述疫苗由下列体积比的原料组成：甲型肝炎减毒活疫苗∶冻干保护剂＝1∶0.5～1.5，其中冻干保护剂即海藻糖与甘氨酸的混合水溶液的组成为：海藻糖2～10克\u002F100毫升，甘氨酸3.2～16克\u002F100毫升，溶剂为水，其中溶质甘氨酸与海藻糖的质量比即甘氨酸∶海藻糖≥1.6。将疫苗与冻干保护剂混合合，经过冻干工艺制得。本发明提供的冻干甲型肝炎减毒活疫苗与现有的液体疫苗相比，冻干后其感染性滴度无显著变化，但其热稳定性显著提高，并且经动物实验证实具有良好的安全性与免疫原性。冻干甲型肝炎减毒活疫苗的有效期可延长至18个月，而液体剂型只为6个月，具有重大经济效益和应用价值。","2009.01.07#公开;2009.02.25#实质审查的生效;2012.03.28#授权","CN200810058812.6","A61K39\u002F29;A61K47\u002F26;A61P1\u002F16;A61P31\u002F14","胡云章;胡凝珠;任万军;王海漩",[],[],54,1,30,2,{"list":322,"total":334,"page":318,"pageSize":318,"totalPages":334},[323],{"id":324,"name":325,"orgName":326,"school":15,"gender":15,"title":15,"degree":15,"honor":327,"position":328,"researchDirection":329,"intro":15,"province":15,"completeness":330,"avatarAuthorized":18,"sourceUrl":331,"nameValid":19,"tags":332,"tagNames":333},"cmv7rn1er000jddmmau8qulzd","应汉杰","苏州大学","ACADEMICIAN","苏州大学校长","生物制造与酶催化方向专家",80,"chaingraph:\u002F\u002F应汉杰",[],[],35346]